Lipid Nanoparticles to enable engineering or ablation of pathogenic cells in the body

Capstan Therapeutics is focused on advancing targeted in vivo RNA-based therapies through its proprietary technology platform, which centers on targeted lipid nanoparticles (tLNPs). These tLNPs are designed to deliver therapeutic payloads, such as mRNA or gene editing tools, specifically to certain cell types within the body. The platform consists of three key components: a non-viral lipid nanoparticle delivery vehicle for safe and repeat dosing, cell type-specific targeting binders that enhance the delivery of disease-specific payloads, and the payloads themselves, which include mRNA encoding for Chimeric Antigen Receptors (CARs) and gene editing machinery. This innovative approach allows for the engineering of immune cells to target and eliminate pathogenic cells, as well as the modification of the DNA in those cells to treat genetic diseases.

The technology developed by Capstan has broad applications across various disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. The company emphasizes the potential for repeat dosing, tunability for safety and efficacy, and scalable manufacturing, which could facilitate outpatient administration and earlier intervention in disease progression. By leveraging its modular therapeutic product design, Capstan aims to create transformative therapies that can significantly improve clinical outcomes for patients with unmet medical needs.

United States

Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles conjugated with a recombinant protein binder such as monoclonal antibodies (tLNPs) designed to deliver payloads, including mRNA or gene editing tools, that can reprogram specific cell types in vivo. The platform technology has the potential to generate transformative therapies with applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

Capstan Therapeutics

Company Details